Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2214-109x(23)00383-2
PubMed Identifier: 37734807
Publication URI: http://europepmc.org/abstract/MED/37734807
Type: Journal Article/Review
Volume: 11
Parent Publication: The Lancet. Global health
Issue: 10
ISSN: 2214-109X